Gefitinib Long-term Survivor Study

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

NCT00986284 ·Status: SUSPENDED ·Phase: PHASE2

NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.

NCT02347839 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

NCT02824458 ·Status: UNKNOWN ·Phase: PHASE3

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

NCT03381430 ·Status: NOT_YET_RECRUITING ·Phase: NA

Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients

NCT02526537 ·Status: TERMINATED

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

NCT03264794 ·Status: UNKNOWN ·Phase: PHASE4

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

NCT06422546 ·Status: RECRUITING

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

NCT02988141 ·Status: UNKNOWN

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

NCT03292133 ·Status: TERMINATED ·Phase: PHASE2

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

NCT00452244 ·Status: COMPLETED ·Phase: PHASE2

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

NCT03267654 ·Status: UNKNOWN ·Phase: PHASE2

First Line Gefitinib by FDG-PET Metabolic Response

NCT01510990 ·Status: UNKNOWN ·Phase: PHASE2

Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

NCT01017679 ·Status: COMPLETED ·Phase: PHASE2

Acquired Resistant Mechanism of the First-generation EGFR TKIs

NCT02804217 ·Status: UNKNOWN

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164 ·Status: RECRUITING

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

NCT00344773 ·Status: COMPLETED ·Phase: PHASE2

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

NCT03399669 ·Status: UNKNOWN ·Phase: PHASE2

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

NCT00588445 ·Status: COMPLETED ·Phase: PHASE2

Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)

NCT00770588 ·Status: COMPLETED ·Phase: PHASE4

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

NCT02381808 ·Status: UNKNOWN

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

NCT01469000 ·Status: COMPLETED ·Phase: PHASE2

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

NCT00455936 ·Status: COMPLETED ·Phase: PHASE3

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

NCT01955421 ·Status: UNKNOWN ·Phase: PHASE2

Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population

NCT02000531 ·Status: COMPLETED ·Phase: PHASE4

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

NCT01106781 ·Status: COMPLETED